US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
GB8311018D0
(en)
|
1983-04-22 |
1983-05-25 |
Amersham Int Plc |
Detecting mutations in dna
|
US6090406A
(en)
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5223427A
(en)
|
1987-03-31 |
1993-06-29 |
The Scripps Research Institute |
Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
|
US5217879A
(en)
|
1989-01-12 |
1993-06-08 |
Washington University |
Infectious Sindbis virus vectors
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
FR2650840B1
(fr)
|
1989-08-11 |
1991-11-29 |
Bertin & Cie |
Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
|
ATE157012T1
(de)
|
1989-11-03 |
1997-09-15 |
Univ Vanderbilt |
Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
|
US5670488A
(en)
*
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
US5204253A
(en)
|
1990-05-29 |
1993-04-20 |
E. I. Du Pont De Nemours And Company |
Method and apparatus for introducing biological substances into living cells
|
US6770283B1
(en)
|
1990-12-13 |
2004-08-03 |
Bioption Ab |
DNA expression systems based on alphaviruses
|
US6004744A
(en)
|
1991-03-05 |
1999-12-21 |
Molecular Tool, Inc. |
Method for determining nucleotide identity through extension of immobilized primer
|
US6037135A
(en)
|
1992-08-07 |
2000-03-14 |
Epimmune Inc. |
Methods for making HLA binding peptides and their uses
|
CA2134773A1
(en)
|
1992-06-04 |
1993-12-09 |
Robert J. Debs |
Methods and compositions for in vivo gene therapy
|
US9340577B2
(en)
|
1992-08-07 |
2016-05-17 |
Epimmune Inc. |
HLA binding motifs and peptides and their uses
|
US5662907A
(en)
|
1992-08-07 |
1997-09-02 |
Cytel Corporation |
Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
|
US20050271676A1
(en)
|
1993-03-05 |
2005-12-08 |
Epimmune Inc. |
Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
|
CN1135181A
(zh)
|
1993-09-14 |
1996-11-06 |
Cytel有限公司 |
使用泛dr结合肽改变免疫应答
|
US6413935B1
(en)
|
1993-09-14 |
2002-07-02 |
Epimmune Inc. |
Induction of immune response against desired determinants
|
EP0711829A3
(en)
|
1993-09-15 |
1997-07-09 |
Viagene Inc |
Recombinant alphavirus vector
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
WO1995013392A1
(en)
|
1993-11-09 |
1995-05-18 |
Medical College Of Ohio |
Stable cell lines capable of expressing the adeno-associated virus replication gene
|
US5505947A
(en)
|
1994-05-27 |
1996-04-09 |
The University Of North Carolina At Chapel Hill |
Attenuating mutations in Venezuelan Equine Encephalitis virus
|
US5851806A
(en)
|
1994-06-10 |
1998-12-22 |
Genvec, Inc. |
Complementary adenoviral systems and cell lines
|
FR2726285B1
(fr)
|
1994-10-28 |
1996-11-29 |
Centre Nat Rech Scient |
Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
|
PT787200E
(pt)
|
1994-10-28 |
2005-08-31 |
Univ Pennsylvania |
Adenovirus melhorado e metodos para a sua utilizacao
|
US5552350A
(en)
|
1994-12-12 |
1996-09-03 |
Ceramco Inc. |
Low-fusing temperature porcelain
|
JPH10510987A
(ja)
*
|
1994-12-12 |
1998-10-27 |
ジェネティック セラピー,インコーポレイテッド |
改良アデノウイルスベクターおよび生産者細胞
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
US5851796A
(en)
*
|
1995-06-07 |
1998-12-22 |
Yale University |
Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
|
UY24367A1
(es)
|
1995-11-23 |
2000-10-31 |
Boehringer Ingelheim Int |
Vacunas contra tumores y procedimiento para su produccion
|
US5849589A
(en)
|
1996-03-11 |
1998-12-15 |
Duke University |
Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
EP0803573A1
(en)
|
1996-04-25 |
1997-10-29 |
Gesellschaft für Biotechnologische Forschung mbH (GBF) |
Polycistronic expression construct with cytokines for multivalent vaccines
|
US6514731B1
(en)
|
1996-05-24 |
2003-02-04 |
Chiron Corporation |
Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
|
EP0910343A1
(en)
|
1996-07-03 |
1999-04-28 |
University Of Pittsburgh |
Emulsion formulations for hydrophilic active agents
|
US6083716A
(en)
|
1996-09-06 |
2000-07-04 |
The Trustees Of The University Of Pennsylvania |
Chimpanzee adenovirus vectors
|
US5994132A
(en)
*
|
1996-10-23 |
1999-11-30 |
University Of Michigan |
Adenovirus vectors
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
US5849561A
(en)
|
1997-05-22 |
1998-12-15 |
Cornell Research Foundation, Inc. |
Method for the production of non-group C adenoviral vectors
|
ES2180258T3
(es)
|
1998-07-07 |
2003-02-01 |
Transgene Sa |
Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
|
EP1000628A1
(en)
|
1998-09-28 |
2000-05-17 |
Fondation Mondiale Recherche et Prevention SIDA |
Use of antigenic complexes of HIV envelope and HLA class I antigens as HIV vaccine
|
US20030072767A1
(en)
|
1998-09-30 |
2003-04-17 |
Alexander Gaiger |
Compositions and methods for WT1 specific immunotherapy
|
US20080050393A1
(en)
|
1998-12-03 |
2008-02-28 |
Tang Y Tom |
Novel nucleic acids and polypeptides
|
WO2000034445A2
(en)
|
1998-12-07 |
2000-06-15 |
U.S. Medical Research Institute Of Infectious Diseases |
Live attenuated venezuelan equine encephalitis vaccine
|
AU2992600A
(en)
|
1999-02-11 |
2000-08-29 |
Genzyme Corporation |
Antigenic peptide concatomers
|
US7262049B2
(en)
*
|
1999-03-16 |
2007-08-28 |
Dana-Farber Cancer Institute, Inc. |
Pseudotyped lentiviral vectors and uses thereof
|
DE60038011T2
(de)
|
1999-04-08 |
2009-02-12 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
|
JP4637368B2
(ja)
|
1999-04-14 |
2011-02-23 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
アルファウイルスに基づくベクター系を利用する免疫応答を生成するための組成物および方法
|
US8647864B2
(en)
|
1999-04-14 |
2014-02-11 |
Novartis Ag |
Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
|
US6365394B1
(en)
|
1999-09-29 |
2002-04-02 |
The Trustees Of The University Of Pennsylvania |
Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
|
EP1244465A4
(en)
|
1999-12-21 |
2005-01-12 |
Epimmune Inc |
INDUCTION OF CELLULAR IMMUNE RESPONSE TO PROSTATE CANCER BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS
|
US20040248113A1
(en)
|
1999-12-28 |
2004-12-09 |
Alessandro Sette |
Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
|
US7462354B2
(en)
|
1999-12-28 |
2008-12-09 |
Pharmexa Inc. |
Method and system for optimizing minigenes and peptides encoded thereby
|
CA2397998A1
(en)
|
2000-01-28 |
2001-08-02 |
Statens Serum Institut |
Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
|
US7619057B2
(en)
|
2000-01-28 |
2009-11-17 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
|
US20010055596A1
(en)
|
2000-03-24 |
2001-12-27 |
Meagher Madeleine Joy |
Compositions and methods for therapy and diagnosis of colon cancer
|
US6436703B1
(en)
|
2000-03-31 |
2002-08-20 |
Hyseq, Inc. |
Nucleic acids and polypeptides
|
US20040115625A1
(en)
|
2000-10-02 |
2004-06-17 |
Reinhard Ebner |
Cancer gene determination and therapeutic screening using signature gene sets
|
US6783939B2
(en)
|
2000-07-07 |
2004-08-31 |
Alphavax, Inc. |
Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
|
EP1320620B1
(en)
|
2000-09-25 |
2015-01-21 |
The Regents Of The University Of Michigan |
Production of viral vectors
|
US20020137081A1
(en)
|
2001-01-08 |
2002-09-26 |
Olga Bandman |
Genes differentially expressed in vascular tissue activation
|
EP1363660A4
(en)
|
2001-02-01 |
2006-06-21 |
Univ Johns Hopkins |
HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
|
CN1147587C
(zh)
*
|
2001-05-30 |
2004-04-28 |
方炳良 |
一种增强细胞特异性目的基因表达的方法
|
EP1399183B1
(en)
|
2001-05-31 |
2010-06-30 |
Novartis Vaccines and Diagnostics, Inc. |
Chimeric alphavirus replicon particles
|
US20030232324A1
(en)
|
2001-05-31 |
2003-12-18 |
Chiron Corporation |
Chimeric alphavirus replicon particles
|
CA2450470C
(en)
|
2001-06-22 |
2012-08-28 |
The Trustees Of The University Of Pennsylvania |
Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
|
PT1497438E
(pt)
|
2002-04-25 |
2010-02-04 |
Crucell Holland Bv |
Meios e métodos para a produção de vectores de adenovírus
|
ATE405663T1
(de)
|
2002-04-25 |
2008-09-15 |
Crucell Holland Bv |
Stabile adenovirale vektoren und methoden für deren vermehrung
|
AU2003289716A1
(en)
|
2002-09-12 |
2004-04-30 |
Incyte Corporation |
Molecules for diagnostics and therapeutics
|
US20070224201A1
(en)
|
2002-10-02 |
2007-09-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP1571909A4
(en)
|
2002-10-03 |
2009-11-11 |
Idm Pharma Inc |
OPTIMIZED CONSTRUCTIONS WITH SEVERAL EPITOPES AND USES THEREOF
|
WO2004055166A2
(en)
|
2002-12-13 |
2004-07-01 |
Alphavax, Inc. |
Multi-antigenic alphavirus replicon particles and methods
|
BRPI0317276B8
(pt)
|
2002-12-13 |
2021-05-25 |
Alphavax Inc |
método para a preparação de partículas de replicon de alfavírus (arps)
|
GB2398300A
(en)
|
2003-02-17 |
2004-08-18 |
Isis Innovation |
Method and compositions for boosting immune response
|
US7425328B2
(en)
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
WO2005033265A2
(en)
|
2003-04-25 |
2005-04-14 |
Epimmune Inc. |
Optimized multi-epitope constructs and uses thereof
|
US7605235B2
(en)
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
SI1629004T1
(sl)
|
2003-06-05 |
2008-12-31 |
Wyeth Corp |
Imunogeni sestavki, ki vsebujejo vektorski replikon virusa venezuelskega konjskega encefalitisa in antigen za protein paramiksovirusa
|
US7291498B2
(en)
|
2003-06-20 |
2007-11-06 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
PL2163260T3
(pl)
|
2004-01-23 |
2017-12-29 |
Msd Italia S.R.L. |
Szympansie adenowirusowe nośniki szczepionek
|
US8119336B2
(en)
|
2004-03-03 |
2012-02-21 |
Ibis Biosciences, Inc. |
Compositions for use in identification of alphaviruses
|
ATE497785T1
(de)
*
|
2004-04-28 |
2011-02-15 |
Univ Pennsylvania |
Sequenzielle freisetzung immunogener moleküle über adenoviren und adeno-assoziierte viren vermittelte abgaben
|
CA2563500C
(en)
*
|
2004-04-28 |
2016-06-28 |
The Trustees Of The University Of Pennsylvania |
Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
|
WO2006078294A2
(en)
|
2004-05-21 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Alphavirus vectors for respiratory pathogen vaccines
|
EP1751290B1
(en)
|
2004-05-25 |
2014-10-15 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus replicon packaging constructs
|
US20060051405A1
(en)
|
2004-07-19 |
2006-03-09 |
Protiva Biotherapeutics, Inc. |
Compositions for the delivery of therapeutic agents and uses thereof
|
JP2008515795A
(ja)
|
2004-10-04 |
2008-05-15 |
バイオバクシム リミテッド |
Hiv感染患者を治療するための、サブタイプを一致させた不活化全粒子ウイルスワクチン
|
US20060198854A1
(en)
|
2004-12-28 |
2006-09-07 |
Peter Pushko |
Vector platforms derived from the alphavirus vaccines
|
US7220549B2
(en)
|
2004-12-30 |
2007-05-22 |
Helicos Biosciences Corporation |
Stabilizing a nucleic acid for nucleic acid sequencing
|
FR2882557A1
(fr)
|
2005-02-25 |
2006-09-01 |
Centre Nat Rech Scient |
Epitopes de vih et composition pharmaceutique les contenant
|
US7283337B2
(en)
|
2005-03-04 |
2007-10-16 |
Headway Technologies, Inc. |
Abutted exchange bias design for sensor stabilization
|
EP2002003B1
(en)
|
2005-05-27 |
2015-12-30 |
Ospedale San Raffaele S.r.l. |
Gene vector comprising mi-rna
|
ES2735531T3
(es)
|
2005-08-23 |
2019-12-19 |
Univ Pennsylvania |
ARN que contiene nucleósidos modificados y métodos de uso del mismo
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
US8252574B2
(en)
|
2006-02-27 |
2012-08-28 |
The Board Of Regents Of The University Of Texas System |
Pseudoinfectious flavivirus and uses thereof
|
US20090022760A1
(en)
|
2006-09-12 |
2009-01-22 |
Alphavax |
Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
|
US9085638B2
(en)
|
2007-03-07 |
2015-07-21 |
The Johns Hopkins University |
DNA vaccine enhancement with MHC class II activators
|
GB0706914D0
(en)
|
2007-04-10 |
2007-05-16 |
Isis Innovation |
Novel adenovirus vectors
|
CA2687141C
(en)
|
2007-05-22 |
2014-04-01 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
ES2440974T3
(es)
|
2007-05-31 |
2014-01-31 |
Genimmune N.V. |
Constructos poliepitópicos del VPH y uso de los mismos
|
AU2008266807B2
(en)
|
2007-06-21 |
2012-08-16 |
Alphavax, Inc. |
Promoterless cassettes for expression of alphavirus structural proteins
|
US20100015179A1
(en)
|
2007-08-16 |
2010-01-21 |
Frolov Ilya V |
Attenuation of encephalitogenic alphavirus and uses thereof
|
EP2201023A2
(en)
|
2007-09-14 |
2010-06-30 |
GENimmune N.V. |
Affinity tag
|
US20100285050A1
(en)
|
2007-10-05 |
2010-11-11 |
Isis Innovation Limited |
Compositions and Methods
|
GB0719526D0
(en)
|
2007-10-05 |
2007-11-14 |
Isis Innovation |
Compositions and methods
|
JP5627464B2
(ja)
|
2007-11-26 |
2014-11-19 |
ノバルティス アーゲー |
アルファウイルス粒子を生成する方法
|
US20110091496A1
(en)
|
2008-01-19 |
2011-04-21 |
Graham Barney S |
Methods and compositions for the delivery of vaccines to disrupted epithelium
|
US20090253184A1
(en)
|
2008-01-23 |
2009-10-08 |
Introgen Therapeutics, Inc. |
Compositions and methods related to an adenoviral trans-complementing cell line
|
NZ587502A
(en)
|
2008-01-24 |
2012-12-21 |
Univ Texas |
Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
|
US20110142880A1
(en)
|
2008-03-28 |
2011-06-16 |
Franck Yann Lemiale |
Lentivirus-based immunogenic vectors
|
AU2009254168A1
(en)
|
2008-06-03 |
2009-12-10 |
Okairos Ag |
A vaccine for the prevention and therapy of HCV infections
|
WO2010005704A2
(en)
|
2008-06-13 |
2010-01-14 |
New York University |
Novel helper plasmid, defective sindbis viral vectors and methods of use thereof
|
ES2902787T3
(es)
|
2008-07-17 |
2022-03-29 |
Medigen Inc |
Vacunas de ADNi y procedimientos para utilizar las mismas
|
US10369204B2
(en)
|
2008-10-02 |
2019-08-06 |
Dako Denmark A/S |
Molecular vaccines for infectious disease
|
WO2010044515A1
(ko)
|
2008-10-17 |
2010-04-22 |
Lee Jeong-Min |
병뚜껑
|
SG171828A1
(en)
|
2008-11-26 |
2011-07-28 |
Us Gov Health & Human Serv |
Virus like particle compositions and methods of use
|
ES2525707T3
(es)
|
2008-12-01 |
2014-12-29 |
Alphavax, Inc. |
Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
|
DE102008061522A1
(de)
|
2008-12-10 |
2010-06-17 |
Biontech Ag |
Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
|
NZ594355A
(en)
*
|
2009-02-02 |
2012-11-30 |
Okairos Ag |
Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
|
CN101579528B
(zh)
|
2009-06-24 |
2011-06-29 |
中国人民解放军军事医学科学院军事兽医研究所 |
一种hiv复合多表位dna疫苗及其应用
|
GB0918154D0
(en)
|
2009-10-16 |
2009-12-02 |
Isis Innovation |
Mycobacterial vaccines
|
US9101572B2
(en)
|
2009-12-31 |
2015-08-11 |
Medigen, Inc. |
Infectious DNA vaccines against chikungunya virus
|
GB201006405D0
(en)
|
2010-04-16 |
2010-06-02 |
Isis Innovation |
Poxvirus expression system
|
CN105648056A
(zh)
|
2010-05-14 |
2016-06-08 |
综合医院公司 |
鉴定肿瘤特异性新抗原的组合物和方法
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
US10487332B2
(en)
|
2010-07-06 |
2019-11-26 |
Glaxosmithkline Biologicals Sa |
Immunisation of large mammals with low doses of RNA
|
MX2013000164A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
|
BR112013000391B8
(pt)
|
2010-07-06 |
2022-10-04 |
Novartis Ag |
Composição de emulsão catiônica de óleo em água e seu uso
|
PL3243526T3
(pl)
|
2010-07-06 |
2020-05-18 |
Glaxosmithkline Biologicals S.A. |
Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
CN103052400B
(zh)
|
2010-07-06 |
2016-11-16 |
诺华股份有限公司 |
自我复制rna分子的病毒样递送颗粒
|
WO2012024350A2
(en)
|
2010-08-16 |
2012-02-23 |
Salk Institute For Biological Studies |
Anti-cancer adenoviruses
|
DK3981427T3
(da)
|
2010-08-31 |
2022-07-11 |
Glaxosmithkline Biologicals Sa |
Pegylerede liposomer til afgivelse af immunogen-kodende RNA
|
FI4043040T3
(fi)
|
2010-08-31 |
2023-04-04 |
Glaxosmithkline Biologicals Sa |
Pieniä liposomeja immunogeeniä koodaavan rna:n toimittamiseksi
|
ES2727583T3
(es)
|
2010-08-31 |
2019-10-17 |
Glaxosmithkline Biologicals Sa |
Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
|
KR20210131432A
(ko)
|
2010-12-30 |
2021-11-02 |
파운데이션 메디신 인코포레이티드 |
종양 샘플의 다유전자 분석의 최적화
|
US9487563B2
(en)
|
2011-01-31 |
2016-11-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Virus-like particles and methods of use
|
US8722044B2
(en)
|
2011-03-15 |
2014-05-13 |
Janssen Biotech, Inc. |
Human tissue factor antibody and uses thereof
|
WO2012158613A1
(en)
|
2011-05-13 |
2012-11-22 |
Novartis Ag |
Pre-fusion rsv f antigens
|
RS64230B1
(sr)
|
2011-05-24 |
2023-06-30 |
BioNTech SE |
Individualizovane vakcine protiv kancera
|
GB201108879D0
(en)
|
2011-05-25 |
2011-07-06 |
Isis Innovation |
Vector
|
WO2012171541A1
(en)
|
2011-06-15 |
2012-12-20 |
Scil Proteins Gmbh |
Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
|
SG10201605537XA
(en)
|
2011-07-06 |
2016-09-29 |
Novartis Ag |
Liposomes having useful n:p ratio for delivery of rna molecules
|
ES2656050T3
(es)
|
2011-07-06 |
2018-02-22 |
Glaxosmithkline Biologicals Sa |
Composiciones de combinación inmunogénica y usos de las mismas
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
KR102067760B1
(ko)
|
2011-08-16 |
2020-01-17 |
삼성전자주식회사 |
세포 내 전달용 단백질 복합체 및 그의 용도
|
TR201900264T4
(tr)
|
2011-08-31 |
2019-02-21 |
Glaxosmithkline Biologicals Sa |
İmmünojen şifreleyici rna'nın verilmesi için pegile edilmiş lipozomlar.
|
WO2013055905A1
(en)
|
2011-10-11 |
2013-04-18 |
Novartis Ag |
Recombinant self-replicating polycistronic rna molecules
|
AP2014007864A0
(en)
|
2012-02-16 |
2014-08-31 |
Vlp Therapeutics Llc |
Virus like particle composition
|
US20160289674A1
(en)
|
2012-04-02 |
2016-10-06 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of membrane proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
CA2873509A1
(en)
|
2012-05-18 |
2013-11-21 |
The Trustees Of The University Of Pennsylvania |
Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
|
ES2663688T3
(es)
|
2012-07-04 |
2018-04-16 |
Sirion Biotech Gmbh |
Medios y métodos para aumentar la producción de adenovirus
|
WO2014005958A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
US8961995B2
(en)
|
2012-09-20 |
2015-02-24 |
Uab Research Foundation |
Methods and compositions for alphavirus replicons
|
GB201220119D0
(en)
|
2012-11-08 |
2012-12-26 |
Univ Cork |
Vector
|
SG11201503864TA
(en)
|
2012-11-16 |
2015-06-29 |
Beth Israel Hospital |
Recombinant adenoviruses and use thereof
|
KR101429696B1
(ko)
*
|
2012-11-21 |
2014-08-13 |
국립암센터 |
안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
|
US9402888B2
(en)
|
2013-03-14 |
2016-08-02 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating cancer
|
KR102341899B1
(ko)
|
2013-04-07 |
2021-12-21 |
더 브로드 인스티튜트, 인코퍼레이티드 |
개인맞춤화 신생물 백신을 위한 조성물 및 방법
|
CA2913832C
(en)
|
2013-06-03 |
2023-07-04 |
Vlp Therapeutics, Llc |
A virus-like particle comprising a malaria antigen and use thereof as a malaria vaccine
|
HUE043042T2
(hu)
*
|
2013-11-01 |
2019-07-29 |
Pfizer |
Vektorok prosztatához kapcsolódó antigének expressziójára
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
BR112016012862A2
(pt)
|
2013-12-06 |
2017-09-26 |
Broad Inst Inc |
formulações para vacinas para neoplasia
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
KR20190062617A
(ko)
|
2014-09-03 |
2019-06-05 |
버베리안 노딕 에이/에스 |
면역 반응을 증대시키기 위한 방법 및 조성물
|
PL3223850T3
(pl)
|
2014-11-26 |
2020-08-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Receptory limfocytów t przeciwko zmutowanemu kras
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
CN107405393A
(zh)
|
2015-01-29 |
2017-11-28 |
新加坡科技研究局 |
携带基孔肯亚相关肽的纳米胶囊
|
US20180030140A1
(en)
|
2015-02-06 |
2018-02-01 |
Navigo Proteins Gmbh |
Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
|
WO2016154047A2
(en)
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
CN115873129A
(zh)
|
2015-03-23 |
2023-03-31 |
约翰·霍普金斯大学 |
由体细胞突变基因编码的hla限制性表位
|
KR20180010229A
(ko)
|
2015-05-20 |
2018-01-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
공유 신생항원
|
DK4104687T3
(da)
|
2015-09-21 |
2024-03-04 |
Trilink Biotechnologies Llc |
Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe
|
CN108601820A
(zh)
|
2015-10-12 |
2018-09-28 |
南托米克斯有限责任公司 |
用于病毒癌症新表位的组合物和方法
|
AU2016369519B2
(en)
|
2015-12-16 |
2023-04-20 |
Gritstone Bio, Inc. |
Neoantigen identification, manufacture, and use
|
KR20220018627A
(ko)
|
2016-02-29 |
2022-02-15 |
파운데이션 메디신 인코포레이티드 |
종양 돌연변이 부담을 평가하기 위한 방법 및 시스템
|
AU2017225787B2
(en)
|
2016-03-03 |
2021-09-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
US20190307868A1
(en)
|
2016-03-31 |
2019-10-10 |
Neon Therapeutics, Inc. |
Neoantigens and methods of their use
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
CA3022267A1
(en)
|
2016-05-04 |
2017-11-09 |
Fred Hutchinson Cancer Research Center |
Cell-based neoantigen vaccines and uses thereof
|
WO2017208191A1
(en)
|
2016-06-02 |
2017-12-07 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
EP3471758A1
(en)
|
2016-06-20 |
2019-04-24 |
ISA Pharmaceuticals B.V |
Formulation of a peptide vaccine
|
GB2549809C
(en)
|
2016-06-23 |
2022-11-30 |
Univ Oxford Innovation Ltd |
Vector
|
CN107698593A
(zh)
|
2016-08-09 |
2018-02-16 |
南京天印健华医药科技有限公司 |
作为fgfr抑制剂的杂环化合物
|
WO2018039131A1
(en)
|
2016-08-22 |
2018-03-01 |
Protiva Biotherapeutics, Inc. |
Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
|
WO2018098362A1
(en)
*
|
2016-11-23 |
2018-05-31 |
Gritstone Oncology, Inc. |
Viral delivery of neoantigens
|
WO2018102585A1
(en)
|
2016-11-30 |
2018-06-07 |
Advaxis, Inc. |
Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
|
EP3551644B1
(en)
|
2016-12-09 |
2023-08-16 |
GlaxoSmithKline Biologicals SA |
Chimpanzee adenovirus constructs with lyssavirus antigens
|
GB201620968D0
(en)
*
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
GB201621732D0
(en)
|
2016-12-20 |
2017-02-01 |
Agricultural Research Council |
A multi-epitope dna vaccine for heartwater
|
AU2017379901B2
(en)
|
2016-12-21 |
2024-02-15 |
Arbutus Biopharma Corporation |
Methods for ameliorating infusion reactions
|
CN108064305B
(zh)
*
|
2017-03-24 |
2021-10-08 |
清华大学 |
可编程的溶瘤病毒疫苗系统及其应用
|
CN111093691A
(zh)
|
2017-04-03 |
2020-05-01 |
内恩疗法公司 |
蛋白质抗原及其用途
|
WO2018208856A1
(en)
|
2017-05-08 |
2018-11-15 |
Gritstone Oncology, Inc. |
Alphavirus neoantigen vectors
|
CA3066635A1
(en)
|
2017-06-09 |
2018-12-13 |
Gritstone Oncology, Inc. |
Neoantigen identification, manufacture, and use
|
AR112166A1
(es)
|
2017-06-16 |
2019-09-25 |
Arbutus Biopharma Corp |
Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
|
KR20200093518A
(ko)
|
2017-07-21 |
2020-08-05 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
JP7232476B2
(ja)
|
2017-08-07 |
2023-03-08 |
ザ ジョンズ ホプキンス ユニバーシティ |
がんを評価及び治療するための方法及び物質
|
WO2019090156A1
(en)
|
2017-11-03 |
2019-05-09 |
Guardant Health, Inc. |
Normalizing tumor mutation burden
|
EP3762512A1
(en)
|
2018-03-06 |
2021-01-13 |
Cancer Research Technology Limited |
Improvements in variant detection
|
US20210213122A1
(en)
|
2018-05-23 |
2021-07-15 |
Gritstone Oncology, Inc. |
Immune checkpoint inhibitor co-expression vectors
|
EP3796927A4
(en)
|
2018-05-23 |
2022-04-20 |
Gritstone bio, Inc. |
SHARED ANTIGENS
|
AU2019374874A1
(en)
|
2018-11-07 |
2021-06-10 |
Gritstone Bio, Inc. |
Alphavirus neoantigen vectors and interferon inhibitors
|
KR20220041844A
(ko)
|
2019-07-02 |
2022-04-01 |
그릿스톤 바이오, 인코포레이티드 |
Hiv 항원 및 mhc 복합체
|
EP4125973A4
(en)
|
2019-11-04 |
2024-03-13 |
Gritstone Bio Inc |
NEOANTIGEN VACCINE THERAPY
|
WO2021119545A1
(en)
|
2019-12-11 |
2021-06-17 |
Gritstone Bio, Inc. |
Durable vaccination
|
WO2021142437A1
(en)
|
2020-01-10 |
2021-07-15 |
Gritstone Bio, Inc. |
Cell-free dna monitoring
|
KR20230014694A
(ko)
|
2020-04-21 |
2023-01-30 |
그릿스톤 바이오, 인코포레이티드 |
항원-코딩 카세트
|
WO2022032196A2
(en)
|
2020-08-06 |
2022-02-10 |
Gritstone Bio, Inc. |
Multiepitope vaccine cassettes
|